Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ENLV)

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

GlobeNewswire 3 days ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra(TM) In Patients with Sepsis

GlobeNewswire 7 days ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With Sepsis

GlobeNewswire 8 days ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire March 22, 2024

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Accesswire February 26, 2024

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Accesswire February 21, 2024

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

GlobeNewswire February 7, 2024

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

GlobeNewswire January 17, 2024

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

GlobeNewswire December 20, 2023
View More News ››

Opinion & Analysis (NDAQ:ENLV)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ENLV)

H.C. Wainwright Article on Enlivex

Worth the read for investors and potential investors, https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-a-buy-rating-on-enlivex...
HariboSpeedPeak - July 21, 2022

Price Target $15

Bio Blast Pharma Ltd (NASDAQ:ORPN) had its "buy" rating reaffirmed by analysts at Roth Capital (     ). They now have...
Twistedsteel74 - June 13, 2016

Anyone else out there on these?

Looks to be some good movement upwards here, guessing must be some news coming as financials weren't stellar.
Twistedsteel74 - May 26, 2016

Good Entry point here

Picked up some more, should see some finacials any day now according to the market beat email. Should be about due for some updates soon...
Twistedsteel74 - May 19, 2016

Blood bath

Followed by a huge bath, wow alot of investors took a hit off this one, myself included. Sad how the company handled the chain of news...
Twistedsteel74 - March 18, 2016

Good run this morning!

First seen this on a marketblast email, with a price target of $25 , glad I bought some, looks like in a decent amount of time they may...
Twistedsteel74 - March 16, 2016
View more Bullboard ››

Xcyte Digital Corp.

Xcyte Digital Corp.

Xcyte Digital is a virtual event company focused on simplifying the event hosting industry and expanding event hosting ...
View More »